Oncotype DX in Women and Men with ER-PR-Positive, HER2-Negative, Early Stage Breast Cancer with Lymph Node Micrometastasis: Clinical Effectiveness, Cost-Effectiveness, and Guidelines


( Last Updated : June 29, 2016)
Project Line:
Reference List
Project Sub Line:
Reference List
Project Number:
RA0855-000

Details


Question


  1. In the adjuvant treatment setting, what is the clinical effectiveness of Oncotype DX in women and men with ER-PR-positive, HER2-negative early stage breast cancer with one lymph node micrometastasis?

  2. In the adjuvant treatment setting, what is the cost-effectiveness of Oncotype DX in women and men with ER-PR-positive, HER2-negative early stage breast cancer with one lymph node micrometastasis?

  3. What are the evidence-based guidelines regarding the use of Oncotype DX in women and men with ER-PR-positive, HER2-negative early stage breast cancer with one lymph node micrometastasis?


Key Message

One evidence-based guideline was identified regarding the use of Oncotype DX in women and men with ER-PR-positive, HER2-negative early stage breast cancer with one lymph node micrometastasis.